Loading
NASDAQHealthcareBiotechnology
Latest quote
$7.57
−$0.21 · -2.70%
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Latest quote
$7.57
−$0.21 · -2.70%
Regular session · ET · Market data may be delayed.
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
40
Expensive
Sentiment
59
Mixed
Risk
58
Elevated Risk
Momentum
39
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 21.33M USD | 16.08M USD | 15.33M USD | 13.63M USD | 10.17M USD |
| Selling, general, and administrative | 17.1M USD | 10.92M USD | 5.63M USD | 3.99M USD | 8.2M USD |
| Operating expenses | 38.43M USD | 27M USD | 20.97M USD | 17.62M USD | 18.38M USD |
| Interest income | 1.41M USD | 1.16M USD | 649.75K USD | 431.8K USD | — |
| Interest expense | — | 603.57K USD | 881.05K USD | 982.86K USD | 1.16M USD |
| Depreciation and amortization | 237.72K USD | 171.72K USD | 117.1K USD | 147.89K USD | 87.47K USD |
| Operating income | −38.43M USD | −27M USD | −20.97M USD | −17.62M USD | −18.38M USD |
| Net income | −38.58M USD | −25.5M USD | −21.25M USD | −18.49M USD | −23.96M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
